All Articles

Genetics and genomics are playing an important role in cancer risk assessment. The Novant Health Cancer Risk Clinic was designed to assist patients and healthcare providers in addressing the complex issues of cancer risk related to genetic mutations and/or familial history of cancer.

This project highlights the importance of nurse navigators and interdisciplinary collaboration and demonstrates how they positively affect healthcare and patient outcomes.

Opening access for all rural areas in the state to participate in multidisciplinary virtual tumor boards (VTBs) could impact overall quality of care for South Carolina cancer patients.

The CNA will allow the LSCVAMC to identify barriers to cancer care and potential areas for improvement to ensure continuous quality improvement and access for our veterans with cancer.

Due to the lack of effective medical treatments for the most common type, pancreatic ductal adenocarcinoma (PDAC), early detection is imperative in treating the disease.

The tissue expansion process using standard of care, saline-filled expanders is lengthy, inconvenient, and uncomfortable and may lead women to make the decision to decline breast reconstruction. The efficacy and safety of a novel, needle-free, patient-controlled tissue expander using CO₂ as the filling medium was compared with the standard of care in the US-based XPAND study.

Cancer clinical research is essential to producing evidence-based clinical care that offers better treatment outcomes. Yet the recruiting and consenting process for cancer clinical trials can be challenging and lead to slow-accruing clinical research and dissatisfaction.

We reviewed the personal and family histories of patients found to have multiple pathogenic or likely pathogenic mutations when tested clinically for 19 genes for hereditary breast and ovarian cancer and the implications for the patient and his or her family.

Patients with chemorefractory non-Hodg­kin lymphoma (NHL) have poor response to standard therapy and short overall survival. The objectives of the phase 1 ZUMA-1 trial were to evaluate the safety and efficacy of KTE-C19, an autologous, anti-CD19 chimeric antigen receptor (CAR) T-cell therapy in patients with chemorefractory NHL.

Stomatitis is a common adverse event (AE) of mTOR inhibition. Nurses are critical in educating patients about and treatment of AEs.